On November 10, 2026, BTIG reaffirmed its Buy rating on Humacyte Inc (HUMA).
Among two firms active over the past 90 days, one holds a bullish rating. The consensus price targets from eight analysts as of November 6, 2026, have a mean of $1.66, a median of $1.15 and a range of $0.51 to $4.20.
Consensus Q4 FY2026 EPS is -$0.09, with revenue at $1.87 million. The next earnings report is on March 25, 2027.
